In this video, Paul Richardson, MD, director of clinical research at Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, discusses the phase III DETERMINATION study in multiple myeloma presented at ASCO Annual Meeting.
Richardson discusses one of the major findings of the study, which was a significant difference between the length of progression-free survival between the early transplant arm of the cohort and the no-transplant arm.
“This was really encouraging and we thought quite remarkable, and to some extent unexpected,” Richardson said. “We expected at
